Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Acquisitions (2017 - 2018)

Historic Acquisitions for Ptc Therapeutics (PTCT) over the last 2 years, with Q3 2018 value amounting to $48.9 million.

  • Ptc Therapeutics' Acquisitions rose 16397.47% to $48.9 million in Q3 2018 from the same period last year, while for Dec 2019 it was $48.9 million, marking a year-over-year increase of 27758.24%. This contributed to the annual value of $48.9 million for FY2018, which is N/A changed from last year.
  • As of Q3 2018, Ptc Therapeutics' Acquisitions stood at $48.9 million, which was up 16397.47% from -$76.4 million recorded in Q3 2017.
  • Ptc Therapeutics' Acquisitions' 5-year high stood at $48.9 million during Q3 2018, with a 5-year trough of -$76.4 million in Q3 2017.